Frontlight ResearchEarly access
Not yet taking people in United StatesNo phase
Pivotal U.S. Clinical Validation of AI-COA® for Depression and Anxiety
Key facts
- Who runs it
- Deliberate Solutions Inc.
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 650 people, planned
- Starts
- 1 Mar 2027
- Expected to end
- 28 Aug 2029
- Type of study
- Observational
- Record updated
- 12 December 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- English fluency
- 18 to 65 years of age
- Diagnosed with MDD or MDE (Includes Remission, HAM-D <= 7)
- Starting, or has started, a new treatment for depression or anxiety within 2-3 weeks of enrollment
- Access to a laptop or other computer with a well functioning microphone and webcam, and a stable Internet connection
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Resides in the United States at the time of consent and during completion of study
Who cannot take part
- Concurrent medication/treatment:; Receiving any fast-acting treatment for depression or anxiety (e.g. ketamine, psychedelics, deep brain stimulation, etc.) in between initial baseline assessment (A1) and Restest (A2) , or in between Follow up assessment (B1) and Retest (B2); Anxiolytics: Use of benzodiazepines or other anxiety-reducing medications that could affect speech or motor activity, within the past 4 weeks; Antipsychotics and Mood Stabilizers: Medications that can alter cognitive and motor functions, within the past 6 weeks; Stimulants: Use of medications like methylphenidate or amphetamines that affect energy levels and behavior, within the past 2 weeks; Epilepsy medication: seizure activity or medication side effects that may alter behavior, within the past 4 weeks
- Participants who have previously participated in another research project by Deliberate
- Any cognitive impairment that limits ability to provide informed consent or authorization
- Impairment that would prevent participants from completing an online survey and/or engaging in clinician assessment interviews (e.g., visual impairment, motor impairment, hearing impairment)
- Any history or evidence of any of the following conditions:; Neurodevelopmental, Neurocognitive, Neurodegenerative or movement disorders including, but not limited to:; Tourette's syndrome; Multiple Sclerosis; Amyotrophic Lateral Sclerosis; Parkinson's Disease; Stroke; Traumatic Brain Injury; Facial paralysis
- Conditions with vocal cord impact:; Vocal cord injury or cerebrovascular accident or head trauma with residual dysarthria in the past year; Disorders that may impact vocal cords such as acute or chronic laryngitis, vocal cord paresis or paralysis, or spasmodic dysphonia; Past or active heavy smokers (an average of >20 cigarettes per day)
- Schizophrenia Spectrum and Other Psychotic Disorders:; Individuals with a current or past diagnosis of Schizophrenia, Schizoaffective Disorder, or other psychotic disorders, including Delusional Disorder and Brief Psychotic Disorder; Current hypomanic episode as defined by DSM-5 criteria. This includes those with Bipolar I Disorder, Bipolar II Disorder, or Cyclothymic Disorder who are not in a stable mood state at the time of assessment; Chronic Pain Conditions: Such as fibromyalgia, which may affect facial expressions and vocal tone; Prosthetic Facial Devices: Could affect facial recognition algorithms. Cosmetic Procedures: Such as Botox injections or facelifts that can impact facial expressions; Dental Work: Major procedures that might affect speech
- Vulnerable or protected populations (e.g. prisoners)
- Acute intoxication at the time of the assessments
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Baylor College of MedicineHouston, United StatesContact: Eric Storch, PhDNot yet recruiting
About the trial
What the trial wants to find out
This study is a large-scale pivotal clinical validation of the AI-COA® software device. The purpose is to confirm the tool's accuracy and performance across a demographically diverse population of adults with Major Depressive Disorder (MDD), ensuring it functions fairly and reliably across different subgroups.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Symptom Evaluation and Quantification for Unified Outcomes and Individualized Assessment: Pivotal Clinical Validation Phase
- Fit questions
- Built from NCT07279038, who can take part
- Record updated
- 12 December 2025